Aprea Therapeutics (APRE) Competitors $3.08 -0.26 (-7.78%) (As of 12/18/2024 05:44 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends APRE vs. RPTX, VOR, VHAQ, BCAB, CUE, SLS, OSTX, INCR, DBVT, and ONCYShould you be buying Aprea Therapeutics stock or one of its competitors? The main competitors of Aprea Therapeutics include Repare Therapeutics (RPTX), Vor Biopharma (VOR), Viveon Health Acquisition (VHAQ), BioAtla (BCAB), Cue Biopharma (CUE), SELLAS Life Sciences Group (SLS), OS Therapies (OSTX), InterCure (INCR), DBV Technologies (DBVT), and Oncolytics Biotech (ONCY). These companies are all part of the "pharmaceutical products" industry. Aprea Therapeutics vs. Repare Therapeutics Vor Biopharma Viveon Health Acquisition BioAtla Cue Biopharma SELLAS Life Sciences Group OS Therapies InterCure DBV Technologies Oncolytics Biotech Repare Therapeutics (NASDAQ:RPTX) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, community ranking, dividends, media sentiment, institutional ownership, analyst recommendations and profitability. Do insiders & institutionals believe in RPTX or APRE? 85.1% of Repare Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 21.6% of Repare Therapeutics shares are owned by insiders. Comparatively, 12.8% of Aprea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in RPTX or APRE? Aprea Therapeutics received 12 more outperform votes than Repare Therapeutics when rated by MarketBeat users. However, 64.62% of users gave Repare Therapeutics an outperform vote while only 56.25% of users gave Aprea Therapeutics an outperform vote. CompanyUnderperformOutperformRepare TherapeuticsOutperform Votes4264.62% Underperform Votes2335.38% Aprea TherapeuticsOutperform Votes5456.25% Underperform Votes4243.75% Which has stronger earnings & valuation, RPTX or APRE? Aprea Therapeutics has lower revenue, but higher earnings than Repare Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRepare Therapeutics$66.52M0.81-$93.80M-$2.00-0.63Aprea Therapeutics$580K28.86-$14.29M-$2.81-1.10 Is RPTX or APRE more profitable? Repare Therapeutics has a net margin of -99.76% compared to Aprea Therapeutics' net margin of -1,029.50%. Repare Therapeutics' return on equity of -40.87% beat Aprea Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Repare Therapeutics-99.76% -40.87% -35.07% Aprea Therapeutics -1,029.50%-57.86%-47.94% Does the media favor RPTX or APRE? In the previous week, Repare Therapeutics had 14 more articles in the media than Aprea Therapeutics. MarketBeat recorded 19 mentions for Repare Therapeutics and 5 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 0.40 beat Repare Therapeutics' score of 0.04 indicating that Aprea Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repare Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 12 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Aprea Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate RPTX or APRE? Repare Therapeutics currently has a consensus target price of $7.00, indicating a potential upside of 455.56%. Aprea Therapeutics has a consensus target price of $15.50, indicating a potential upside of 403.25%. Given Repare Therapeutics' higher probable upside, analysts clearly believe Repare Therapeutics is more favorable than Aprea Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Repare Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Aprea Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, RPTX or APRE? Repare Therapeutics has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. SummaryRepare Therapeutics beats Aprea Therapeutics on 12 of the 18 factors compared between the two stocks. Ad Porter & CompanyAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.I urge you to watch it now. Get Aprea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APRE vs. The Competition Export to ExcelMetricAprea TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.74M$6.71B$5.03B$8.97BDividend YieldN/A3.07%4.80%4.06%P/E Ratio-1.1010.40134.6816.91Price / Sales28.86187.361,134.38116.20Price / CashN/A57.1640.5137.94Price / Book0.685.194.744.71Net Income-$14.29M$151.85M$118.37M$225.20M7 Day Performance-12.50%-5.29%11.28%-2.58%1 Month Performance1.99%-4.63%9.41%3.57%1 Year Performance-21.03%9.45%29.70%16.54% Aprea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APREAprea Therapeutics3.2687 of 5 stars$3.08-7.8%$15.50+403.2%-23.2%$16.74M$580,000.00-1.107Analyst ForecastNews CoverageRPTXRepare Therapeutics3.4098 of 5 stars$1.61-9.0%$7.00+334.8%-80.4%$68.44M$51.13M-0.89180High Trading VolumeVORVor Biopharma2.158 of 5 stars$0.99+0.4%$11.36+1,041.5%-61.1%$68.32MN/A-0.60140VHAQViveon Health AcquisitionN/A$10.00flatN/AN/A$66.49MN/A0.002BCABBioAtla2.7029 of 5 stars$1.37-5.5%$6.00+338.0%-40.6%$66.23M$11M-0.8560Gap UpCUECue Biopharma4.6484 of 5 stars$1.04+10.6%$5.00+380.8%-62.1%$65.88M$9.53M-1.1660Short Interest ↓News CoveragePositive NewsGap DownSLSSELLAS Life Sciences Group0.0195 of 5 stars$0.93+7.1%N/A-24.9%$65.74M$1M-1.3916OSTXOS TherapiesN/A$3.09+2.3%$8.00+158.9%N/A$65.63MN/A0.00N/ANews CoverageGap DownINCRInterCure0.2389 of 5 stars$1.43+8.2%N/A+13.2%$64.94M$272.67M0.00350Gap UpDBVTDBV Technologies3.5951 of 5 stars$3.13-12.3%$22.50+618.8%-64.7%$64.38M$15.73M-0.73106Analyst ForecastONCYOncolytics Biotech2.2711 of 5 stars$0.83+1.4%$4.00+384.8%-41.6%$63.58MN/A-3.0030News Coverage Related Companies and Tools Related Companies RPTX Competitors VOR Competitors VHAQ Competitors BCAB Competitors CUE Competitors SLS Competitors OSTX Competitors INCR Competitors DBVT Competitors ONCY Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:APRE) was last updated on 12/19/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aprea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
